In its 2022 election statement, InGeNA says the incoming government has the opportunity to build on Australia’s growing genomics expertise and enable consumers to benefit from the new age of precision health.

Future directions for health technology assessment in Australia provides a unified industry viewpoint on how the reform of the HTA system could substantially improve and enhance access to genomic technology for health consumers.

InGeNA commissioned Deloitte Access Economics to conduct research which will provide a snapshot of the potential value of genomics on healthcare in Australia by profiling a suite of case study applications across the screening, diagnosis, and treatment stages of the care continuum.

An industry perspective on clarity, certainty and standardisation, the first industry-led report on data sharing and the challenges facing governance around genomic data, is published by the Industry Genomics Network Alliance (InGeNA).